NO317517B1 - Anvendelse av hepariner med lav molekylvekt for fremstilling av medikamenter for terapi av sentralnervesystemtrauma - Google Patents
Anvendelse av hepariner med lav molekylvekt for fremstilling av medikamenter for terapi av sentralnervesystemtrauma Download PDFInfo
- Publication number
- NO317517B1 NO317517B1 NO19995538A NO995538A NO317517B1 NO 317517 B1 NO317517 B1 NO 317517B1 NO 19995538 A NO19995538 A NO 19995538A NO 995538 A NO995538 A NO 995538A NO 317517 B1 NO317517 B1 NO 317517B1
- Authority
- NO
- Norway
- Prior art keywords
- molecular weight
- low molecular
- trauma
- heparin
- therapy
- Prior art date
Links
- 229940127215 low-molecular weight heparin Drugs 0.000 title claims description 17
- 210000003169 central nervous system Anatomy 0.000 title claims description 10
- 229940079593 drug Drugs 0.000 title claims description 7
- 239000003814 drug Substances 0.000 title claims description 7
- 238000002560 therapeutic procedure Methods 0.000 title claims description 7
- 208000001738 Nervous System Trauma Diseases 0.000 title description 3
- 238000004519 manufacturing process Methods 0.000 title description 2
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims description 24
- 208000014674 injury Diseases 0.000 claims description 22
- 230000008733 trauma Effects 0.000 claims description 22
- 229920000669 heparin Polymers 0.000 claims description 20
- 229960002897 heparin Drugs 0.000 claims description 12
- 239000003055 low molecular weight heparin Substances 0.000 claims description 8
- -1 heparin ester Chemical class 0.000 claims description 5
- 229960000610 enoxaparin Drugs 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 3
- 239000002253 acid Substances 0.000 claims description 2
- 229940090880 ardeparin Drugs 0.000 claims description 2
- 229940107792 certoparin Drugs 0.000 claims description 2
- 229960003828 danaparoid Drugs 0.000 claims description 2
- XEKSTYNIJLDDAZ-JASSWCPGSA-D decasodium;(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5r,6r)-6-[(2r,3s,4s,5r,6r)-2-carboxylato-4-hydroxy-6-[(2r,3s,4r,5r,6s)-4-hydroxy-6-methoxy-5-(sulfonatoamino)-2-(sulfonatooxymethyl)oxan-3-yl]oxy-5-sulfonatooxyoxan-3-yl]oxy-5-(sulfonatoamino)-4-sulfonatooxy-2-(sul Chemical compound [Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].O[C@@H]1[C@@H](NS([O-])(=O)=O)[C@@H](OC)O[C@H](COS([O-])(=O)=O)[C@H]1O[C@H]1[C@H](OS([O-])(=O)=O)[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](OS([O-])(=O)=O)[C@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O[C@@H]4[C@@H]([C@@H](O)[C@H](O)[C@@H](COS([O-])(=O)=O)O4)NS([O-])(=O)=O)[C@H](O3)C([O-])=O)O)[C@@H](COS([O-])(=O)=O)O2)NS([O-])(=O)=O)[C@H](C([O-])=O)O1 XEKSTYNIJLDDAZ-JASSWCPGSA-D 0.000 claims description 2
- 229960000899 nadroparin Drugs 0.000 claims description 2
- 229920001542 oligosaccharide Polymers 0.000 claims description 2
- 150000002482 oligosaccharides Chemical class 0.000 claims description 2
- 229960004762 parnaparin Drugs 0.000 claims description 2
- 229960005496 reviparin Drugs 0.000 claims description 2
- 229960005062 tinzaparin Drugs 0.000 claims description 2
- 239000000203 mixture Substances 0.000 description 9
- 230000003902 lesion Effects 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- GQPLMRYTRLFLPF-UHFFFAOYSA-N Nitrous Oxide Chemical compound [O-][N+]#N GQPLMRYTRLFLPF-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 230000002490 cerebral effect Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000005194 fractionation Methods 0.000 description 3
- 208000027232 peripheral nervous system disease Diseases 0.000 description 3
- 208000033808 peripheral neuropathy Diseases 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 208000032843 Hemorrhage Diseases 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 210000001951 dura mater Anatomy 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 230000023597 hemostasis Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 210000003497 sciatic nerve Anatomy 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 239000008223 sterile water Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 208000000044 Amnesia Diseases 0.000 description 1
- 208000031091 Amnestic disease Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 239000005662 Paraffin oil Substances 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 206010067633 Peripheral nerve lesion Diseases 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 150000008044 alkali metal hydroxides Chemical class 0.000 description 1
- 239000000908 ammonium hydroxide Substances 0.000 description 1
- 230000006986 amnesia Effects 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 230000001858 anti-Xa Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 210000003050 axon Anatomy 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000013043 chemical agent Substances 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 239000003479 dental cement Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 229960002442 glucosamine Drugs 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- BCQZXOMGPXTTIC-UHFFFAOYSA-N halothane Chemical compound FC(F)(F)C(Cl)Br BCQZXOMGPXTTIC-UHFFFAOYSA-N 0.000 description 1
- 229960003132 halothane Drugs 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000008141 laxative Substances 0.000 description 1
- 229940125722 laxative agent Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 229940118179 lovenox Drugs 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 239000002324 mouth wash Substances 0.000 description 1
- 239000007923 nasal drop Substances 0.000 description 1
- 229940100662 nasal drops Drugs 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 230000000324 neuroprotective effect Effects 0.000 description 1
- 239000001272 nitrous oxide Substances 0.000 description 1
- 230000001936 parietal effect Effects 0.000 description 1
- 238000009527 percussion Methods 0.000 description 1
- KHIWWQKSHDUIBK-UHFFFAOYSA-N periodic acid Chemical compound OI(=O)(=O)=O KHIWWQKSHDUIBK-UHFFFAOYSA-N 0.000 description 1
- 210000000578 peripheral nerve Anatomy 0.000 description 1
- 210000001428 peripheral nervous system Anatomy 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 125000001453 quaternary ammonium group Chemical group 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 238000013222 sprague-dawley male rat Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000003206 sterilizing agent Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000009182 swimming Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 230000009424 thromboembolic effect Effects 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- 239000002966 varnish Substances 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/727—Heparin; Heparan
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR9706550A FR2763848B1 (fr) | 1997-05-28 | 1997-05-28 | Utilisation des heparines de bas poids moleculaire pour la prevention et le traitement du trauma du systeme nerveux central |
| PCT/FR1998/001034 WO1998053833A1 (fr) | 1997-05-28 | 1998-05-25 | Utilisation des heparines de bas poids moleculaire pour la prevention et le traitement du trauma du systeme nerveux central |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO995538D0 NO995538D0 (no) | 1999-11-12 |
| NO995538L NO995538L (no) | 1999-11-12 |
| NO317517B1 true NO317517B1 (no) | 2004-11-08 |
Family
ID=9507335
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO19995538A NO317517B1 (no) | 1997-05-28 | 1999-11-12 | Anvendelse av hepariner med lav molekylvekt for fremstilling av medikamenter for terapi av sentralnervesystemtrauma |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US6380173B1 (zh) |
| EP (2) | EP1421943A1 (zh) |
| JP (1) | JP2002500660A (zh) |
| KR (1) | KR100531721B1 (zh) |
| CN (1) | CN1212845C (zh) |
| AR (1) | AR012876A1 (zh) |
| AT (1) | ATE276752T1 (zh) |
| AU (1) | AU752322B2 (zh) |
| BR (1) | BR9809504A (zh) |
| CA (1) | CA2290675A1 (zh) |
| DE (1) | DE69826460T2 (zh) |
| ES (1) | ES2227841T3 (zh) |
| FR (1) | FR2763848B1 (zh) |
| IL (2) | IL132671A0 (zh) |
| MA (1) | MA24553A1 (zh) |
| NO (1) | NO317517B1 (zh) |
| NZ (1) | NZ501365A (zh) |
| PE (1) | PE74699A1 (zh) |
| PT (1) | PT984786E (zh) |
| RU (1) | RU2215531C2 (zh) |
| TN (1) | TNSN98071A1 (zh) |
| TW (1) | TW533075B (zh) |
| WO (1) | WO1998053833A1 (zh) |
| ZA (1) | ZA984432B (zh) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20010041686A1 (en) * | 2000-01-06 | 2001-11-15 | Veronique Mary | Novel therapeutic application of enoxaparin |
| US9308220B2 (en) | 2001-12-11 | 2016-04-12 | Cosmo Technologies Limited | Pharmaceutical compositions for the oral administration of heparin or derivatives thereof |
| ITMI20012599A1 (it) * | 2001-12-11 | 2003-06-11 | Cosmo Spa | Composizioni farmaceutiche per la somministrazione orale di eparina osuoi derivati, utili per la terapia di malattie infiammatorie dell'int |
| US7511026B2 (en) | 2003-03-25 | 2009-03-31 | Seikagaku Corporation | Therapeutic agent for nerve damage |
| ITMI20031023A1 (it) * | 2003-05-21 | 2004-11-22 | Umberto Cornelli | Glicosaminoglicani aventi peso molecolare medio 2400 d atti al trattamento delle disfunzioni emozionali. |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1195322A (en) * | 1982-07-19 | 1985-10-15 | Eduardo Amaya | Process for manufacturing low molecular weight heparins by depolymerization of normal heparin |
| FR2614026B1 (fr) * | 1987-04-16 | 1992-04-17 | Sanofi Sa | Heparines de bas poids moleculaire, a structure reguliere, leur preparation et leurs applications biologiques |
| IT1243300B (it) * | 1990-12-20 | 1994-05-26 | Fidia Spa | Derivati dell'eparina |
| IT1264530B (it) * | 1992-07-31 | 1996-10-02 | Crinos Industria Farmaco | Impiego dei polisaccaridi nelle neuropatie atrofico degenerative |
-
1997
- 1997-05-28 FR FR9706550A patent/FR2763848B1/fr not_active Expired - Fee Related
-
1998
- 1998-05-19 PE PE1998000386A patent/PE74699A1/es not_active Application Discontinuation
- 1998-05-25 EP EP04003133A patent/EP1421943A1/fr not_active Withdrawn
- 1998-05-25 IL IL13267198A patent/IL132671A0/xx active IP Right Grant
- 1998-05-25 AU AU77759/98A patent/AU752322B2/en not_active Ceased
- 1998-05-25 PT PT98925773T patent/PT984786E/pt unknown
- 1998-05-25 BR BR9809504-8A patent/BR9809504A/pt not_active Application Discontinuation
- 1998-05-25 NZ NZ501365A patent/NZ501365A/xx unknown
- 1998-05-25 AT AT98925773T patent/ATE276752T1/de not_active IP Right Cessation
- 1998-05-25 ES ES98925773T patent/ES2227841T3/es not_active Expired - Lifetime
- 1998-05-25 TW TW087108065A patent/TW533075B/zh not_active IP Right Cessation
- 1998-05-25 DE DE69826460T patent/DE69826460T2/de not_active Expired - Lifetime
- 1998-05-25 KR KR10-1999-7010960A patent/KR100531721B1/ko not_active IP Right Cessation
- 1998-05-25 MA MA25088A patent/MA24553A1/fr unknown
- 1998-05-25 RU RU99128105/14A patent/RU2215531C2/ru not_active IP Right Cessation
- 1998-05-25 CA CA002290675A patent/CA2290675A1/fr not_active Abandoned
- 1998-05-25 WO PCT/FR1998/001034 patent/WO1998053833A1/fr active IP Right Grant
- 1998-05-25 JP JP50031099A patent/JP2002500660A/ja not_active Ceased
- 1998-05-25 CN CNB988054892A patent/CN1212845C/zh not_active Expired - Fee Related
- 1998-05-25 ZA ZA984432A patent/ZA984432B/xx unknown
- 1998-05-25 EP EP98925773A patent/EP0984786B1/fr not_active Expired - Lifetime
- 1998-05-27 TN TNTNSN98071A patent/TNSN98071A1/fr unknown
- 1998-05-27 AR ARP980102470A patent/AR012876A1/es unknown
-
1999
- 1999-11-01 IL IL132671A patent/IL132671A/en not_active IP Right Cessation
- 1999-11-12 NO NO19995538A patent/NO317517B1/no not_active IP Right Cessation
- 1999-11-24 US US09/448,244 patent/US6380173B1/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| DE69826460T2 (de) | 2005-10-13 |
| FR2763848A1 (fr) | 1998-12-04 |
| US6380173B1 (en) | 2002-04-30 |
| AR012876A1 (es) | 2000-11-22 |
| NZ501365A (en) | 2002-12-20 |
| EP0984786A1 (fr) | 2000-03-15 |
| ATE276752T1 (de) | 2004-10-15 |
| EP0984786B1 (fr) | 2004-09-22 |
| NO995538D0 (no) | 1999-11-12 |
| PE74699A1 (es) | 1999-10-21 |
| CN1212845C (zh) | 2005-08-03 |
| ZA984432B (en) | 1998-12-02 |
| AU752322B2 (en) | 2002-09-19 |
| TNSN98071A1 (fr) | 2005-03-15 |
| CA2290675A1 (fr) | 1998-12-03 |
| PT984786E (pt) | 2005-01-31 |
| MA24553A1 (fr) | 1998-12-31 |
| BR9809504A (pt) | 2000-06-20 |
| RU2215531C2 (ru) | 2003-11-10 |
| CN1257428A (zh) | 2000-06-21 |
| KR100531721B1 (ko) | 2005-11-28 |
| TW533075B (en) | 2003-05-21 |
| NO995538L (no) | 1999-11-12 |
| IL132671A0 (en) | 2001-03-19 |
| JP2002500660A (ja) | 2002-01-08 |
| DE69826460D1 (de) | 2004-10-28 |
| IL132671A (en) | 2007-06-17 |
| EP1421943A1 (fr) | 2004-05-26 |
| ES2227841T3 (es) | 2005-04-01 |
| AU7775998A (en) | 1998-12-30 |
| FR2763848B1 (fr) | 2000-01-28 |
| WO1998053833A1 (fr) | 1998-12-03 |
| KR20010012988A (ko) | 2001-02-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU8684698A (en) | Method and compositions for treating late phase allergic reactions and inflammatory diseases | |
| US5605891A (en) | Use of polysaccharides in acute peripheral neuropathies | |
| AU2004224510B2 (en) | Remedy for nerve damage | |
| AP619A (en) | Use of hyaluronic acid or salt for the treatment of a human having a stroke or myocardial infarction. | |
| NO317517B1 (no) | Anvendelse av hepariner med lav molekylvekt for fremstilling av medikamenter for terapi av sentralnervesystemtrauma | |
| US5767106A (en) | Treatment of disease and conditions associated with macrophage infiltration | |
| US6579858B1 (en) | Use of low-molecular-weight heparins for the prevention and treatment of cerebral edemas | |
| NZ517119A (en) | Use of low-molecular-weight heparins for preventing and treating central nervous system (CNS) trauma | |
| MXPA99010595A (en) | Use of low-molecular-weight heparins for preventing and treating cerebral edemas | |
| MXPA99010582A (en) | Use of low-molecular-weight heparins for preventing and treating central nervous system trauma |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM1K | Lapsed by not paying the annual fees |